<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408524</url>
  </required_header>
  <id_info>
    <org_study_id>594/2552(EC4)</org_study_id>
    <nct_id>NCT01408524</nct_id>
  </id_info>
  <brief_title>Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol and Diltiazem</brief_title>
  <official_title>A Comparative Study in the Control of Emergence Blood Pressure During Craniotomy for Tumor Surgery Between Labetolol (Avexa) and Diltiazem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of the antihypertensive drugs in
      the control of emergence blood pressure after tumor resection craniotomy; compared between
      labetalol (Avexa) and diltiazem (Herbessor).

      Also the investigators seek to determine the effective dose of the antihypertensive drugs and
      their side effects in Thai population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was randomized equivalence trial
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of the patients who have systolic blood pressure below 140 mmHg</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean doses of the study drugs</measure>
    <time_frame>3hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of patients with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>6 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Hypertension</condition>
  <condition>Craniotomy</condition>
  <arm_group>
    <arm_group_label>Diltiazem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Labetalol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <description>2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence</description>
    <arm_group_label>Diltiazem</arm_group_label>
    <other_name>Herbessor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol</intervention_name>
    <description>2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence</description>
    <arm_group_label>Labetalol</arm_group_label>
    <other_name>Avexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who scheduled for craniotomy for tomor removal

        Exclusion Criteria:

          -  allergic to labetalol or diltiazem

          -  Bradycardia &lt; 60 beat/min

          -  Second or third degree heart block

          -  Severe asthma or severe COPD

          -  Brain stem tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Busara - Sirivanasandha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, Siriraj Hospital, Mahidol University, Bangkok, Thailand</affiliation>
  </overall_official>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>busara sirivanasandha</investigator_full_name>
    <investigator_title>Miss</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>emergence</keyword>
  <keyword>craniotomy</keyword>
  <keyword>Hypertension during the emergence after craniotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Labetalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

